New pooled data confirm Vimpat's efficacy in the adjunctive treatment of uncontrolled partial-onset seizures in adults. The drug represents a new treatment option for patients with uncontrolled epilepsy, but its inferior efficacy to Keppra is expected to limit its uptake. Nevertheless, future indication expansions in migraine and fibromyalgia may expand Vimpat's commercial potential.
Edit my basket
© Datamonitor 2012. All rights reserved
Terms & Conditions